A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS)

Autor:	Vaia Florou, Deukwoo Kwon, Darcy A. Kerr, Efrosyni Sfakianaki, Jonathan C. Trent, Andrew E. Rosenberg, Ty K. Subhawong, Despina Kolonias, Jaime R. Merchan, Wungki Park, Eric D. Wieder, Krishna V. Komanduri, Matteo Trucco, Breelyn A. Wilky
Rok vydání:	2018
Předmět:	0301 basic medicine Cancer Research biology business.industry VEGF receptors Soft tissue Pembrolizumab medicine.disease Axitinib Vascular endothelial growth factor 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Overall response rate Oncology chemistry 030220 oncology & carcinogenesis Alveolar soft part sarcoma medicine biology.protein Cancer research business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:11547-11547
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.11547
Popis:	11547Background: Inhibition of programmed-death 1 (PD1) by pembrolizumab (P) produced overall response rates (ORR) of 19% in advanced STS [SARC028]. Vascular endothelial growth factor (VEGF) suppre...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::15e947f369f4e9989f64207af7f1a3d0 https://doi.org/10.1200/jco.2018.36.15_suppl.11547 Zobrazit plný text záznamu